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Is Associated With Cardiovascular Risk in
Stable Patients With Diabetes
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EARL B. BRITT, JR., BS

NAVEED IQBAL, MD
STANLEY L. HAZEN,
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OBJECTIVEdTo investigate the relationship between different degrees of subclinical myo
cardial necrosis, glycemic control, and long term adverse clinical outcomes within a stable pa
tient population with diabetes mellitus.
RESEARCH DESIGN AND METHODSdWe examined 1,275 stable patients with di
abetes mellitus undergoing elective diagnostic coronary angiography with cardiac troponin I
(cTnI) levels below the diagnostic cut off for deﬁning myocardial infarction (MI) (,0.03 ng/mL).
The relationship of subclinical myocardial necrosis (cTnI 0.009 0.029 ng/mL) with incident
major adverse cardiovascular events (MACE; deﬁned as any death, MI, or stroke) over 3 years
of follow up was examined.
RESULTSdSubclinical myocardial necrosis was observed in 22% of patients. A strong asso
ciation was observed between the magnitude of subclinical myocardial necrosis and risk of 3 year
incident MACE (hazard ratio, 1.98; 95% conﬁdence interval, 1.48 2.65; P , 0.001) and
remained statistically signiﬁcant even after adjustment for traditional risk factors, high sensitivity
C reactive protein, and creatinine clearance. Only a weak correlation was observed between the
presence of subclinical myocardial necrosis and either glycemic control (r = 0.06; P = 0.044 for
hemoglobin A1c versus cTnI) or insulin resistance (r = 0.04; P = 0.094 for glucose to insulin
ratio versus cTnI).
CONCLUSIONSdThe presence of detectable subclinical myocardial necrosis in stable
patients with diabetes mellitus is associated with heightened long term risk for MACE, indepen
dent of traditional risk factors and glycemic control.

Detection of systemic levels of cardiac
troponin is associated with the
presence of ongoing myocardial
necrosis and fulﬁlls the contemporary
deﬁnition of myocardial infarction (MI)
in the presence of ischemic symptoms (1).
However, a minimal increase in cardiac
troponin levels below the diagnostic
range often provides clinical challenges,
particularly in stable ambulatory patients
without overt signs and symptoms sug
gestive of underlying ischemia and nor
mal renal function (2). As biochemical

assays become more and more sensitive,
the ability to detect minimal myocardial
damage may allow risk assessment in sta
ble cardiac patients beyond the acute
setting (3).
We recently have demonstrated that
such presence of subclinical myocardial
necrosis was associated with adverse long
term cardiovascular risks in stable patients
undergoing elective coronary angiography
(4). These ﬁndings were reported in dia
betic and nondiabetic patients with and
without coronary artery disease and heart

failure. We sought to examine the prognos
tic signiﬁcance of detectable subclinical
myocardial necrosis in the setting of diabe
tes mellitus, particularly to examine its re
lationship with underlying glycemic
control.
RESEARCH DESIGN AND
METHODS The Cleveland Clinic
GeneBank study is a large, prospective,
cohort study that established a well
characterized clinical repository with
clinical data and longitudinal outcomes
from consenting subjects undergoing
elective diagnostic coronary angiography
from 2001 to 2006. All GeneBank partic
ipants gave written informed consent
approved by the Cleveland Clinic Insti
tutional Review Board. All blood samples
were collected at the time of cardiac
catheterization procedure. This analysis
included a cohort of 1,275 consecutive
consenting subjects with a clinical diagno
sis of diabetes mellitus without clinical
evidence of acute coronary syndrome at
the time of enrollment with 3 year follow
up data. These patients underwent elective
diagnostic coronary angiography within 1
year of attending outpatient appointments,
scheduled coronary computed tomogra
phy angiogram scans, or computed tomog
raphy scans within 1 year of scheduled
blood draws. The various reasons for the
elective coronary angiography include
(subjects could have more than one reason
per person) the following: history of pos
itive or indeterminate stress test (50%);
evaluation for possible ischemic causes of
symptoms (68%); preoperative evaluation
(10%); and history of cardiomyopathy
(3%). Subjects included were only those
with cardiac troponin I (cTnI) ,0.03 ng/mL,
no history of revascularization within 30
days before enrollment, and at least 3 years
of adjudicated follow up data. The diag
nosis of diabetes mellitus was determined
based on the latest guideline recommen
dations as clinical history of diabetes mel
litus or fasting glucose $126 mg/dL or
hemoglobin A1c (HbA1c) $6.5% at the
time of enrollment (5).

Plasma levels of cTnI were measured
using the STAT Troponin I assay (Abbott
laboratories, Abbott Park, IL) ina research
based immunoanalyzer that provides a
three decimal point readout from venous
blood samples collected by EDTA tubes.
This assay provides highly sensitive analyt
ical measuremem of cTnl with a reported
limit of detection reaching 0.009 nglmL in
the literature (4) and a diagnostic cut off of
0.03 nglmL for MI defined by the upper
limit of normal (99th percemile cut off
with 10% coefficiem of variation). Based
on the analytical characteristics of the
cTnl assay, we defined subclinical myocar
dial necrosis as cTnl 0.009 0.029 nglmL
(above level of detection). High sensitivity
C reactive protein (hsCRP), HbA 1c , glu
cose, insulin, creatinine, and fasting lipid
profiles all were measured simultaneously
with the cTnl assay using the same analysis
platform. Treating physicians and adjudi
cation commiuee were blinded to the re
sults of cTnl.
We defined coronary angiography as
any clinical history of MI, percutaneous
coronary intervention, coronary artery
by p ass graft, or angiographic evidence of
significantstenosis ( 50%) in one or more
major coronary arteries. Dyslipidemia was
defined as LDL cholesterol > 130 mgldL,
HDL cholesterol <50 mgldL, triglycerides
> 150 mgldL, or the use of lipid lowering
agents. An estimate of creatinine clearance
(eCrO) was calculated using the Cockcroft
Gault equation, because a large majority of
subjects had relatively preserved renal
function. Adjudicated outcomes were
prospectively ascertained over the ensuing
3 years for all subjects after enrollmem.
Maj or adverse cardiovascular event
(MACE) was defined as death, nonfatal MI,
or nonfatal stroke after enrollmem. Non
fatal MI was defined as patients that re
mained alive over the follow up period
of 3 years and met the universal definition
of MI, which is defined as a documented
increase in cardiac biomarker in conjunc
tion with evidence of myocardial ische
mia (1). Nonfatal stroke in this cohort
was defined as patients with a clinical
diagnosis of rapid loss of brain function
attributable to blood flow disturbance to
the brain with accompanying imaging
techniques or records of confirmed diag
nosis who remained alive over the follow
up period of 3 years. All cause death was
ascertained by follow up (1 and 3 year)
telephone interviews, Social Security
Death Index that was assessed periodi
cally after enrollment, official hospital
record, or death certificate.

The Student t test or Wilcoxon rank
sum test for continuous variables and x 2
test for categorical variables were used to
examine the difference between the
groups. Unadjusted trends (adjusted for
age and sex only) for all cause mortality
rates as well as nonfatal Ml/stroke rates
with increasing tertiles of cTnI were eval
uated with the Cochran Armitage test
using a time to event approach. Adjust
ments were made for individual tradi
tional cardiac risk factor, Framingham
risk factors (including age, sex, cigarette
smoking, LDL cholesterol, HDL choles
terol, and systolic blood pressure) plus
log transformed hsCRP, and CrCl to pre
diet incident 3 year MACE risks. Kaplan
Meier analysis with Cox proportional
hazards regression was used for time
to event analysis to determine hazard ra
tio (HR) and 95% confidence intervals
(95% Cis) for MACE. Levels of cTnI
then were adjusted for traditional

coronary angiography risk factors in
a multivariable model including Framing
ham risk factors, log transformed hsCRP,
and CrCl. We confirmed that both the
proportionality hazards and linearity as
sumptions were met. All analyses were
performed using R 2.10.1 (Vienna, Aus
tria). P < 0.05 was considered statistically
significant. The authors had full access
to all of the de identified data in the study
and take responsibility for the integrity
of the data and the accuracy of the data
analysis.

R E S U L T S In our study cohort of
1,275 subjects, 22% of subjects had
evidence of subclinical myocardial necro
sis (with 34% detectable but in the range
of 0.001 0.008 nglmL). The evem num
bers for MACE in our cohort over the
3 year follow up were as follows: all
cause death, 129/1,275; nonfatal MI, 62/
1,275; and nonfatal stroke, 31/1,275.

Table I-Baseline characteristics

Subclinical myocardial necrosis
cTnl range (nglml)
Demographics and clinical data
Age (years)
Male(%)
Systolic blood pressure
History of hy p e n ensi on (%)
History of hean failure (%)
Cigarette smoking (former/current %)
Previous myocardial infarction(%)
Previous revascularization (%)
Maximal stenosis 50% (%)
Number of coronary vessel disease
None(%)
One(%)

Two(%)
Three(%)
HbA 1c (%)
Laboratory data
Fasting LDL cholesterol (mgfdl)
Fasting HDL cholesterol (mgtdl)
Fasting triglycerides (mgfdl)
hsCRP (mgfl)
CrCI (ml./min/1. 73m 2 )
Baseline medications
Aspirin(%)
Statin (%)
ACE inhibitors (%)
Beta blockers (%)
Insulin(%)
Oral glucose lowering drugs(%)

No (n = 989)

Yes (n = 286)

<0.01

0.01 0.03

64 :!: 10
59
136 :!: 21

67 ::!: 10
70
138 ::!: 24
82
38
68
53
40
87

77

16
63
31
31

77

23
19
20
38
6.7 (6.1 7 7)

14
13
21
52
7.0 (6 4 8)

p

<0.001
0.002
0.205
0.111
<0.001
0.17
<0.001
0003
<0.001
0.001
0.017
0606
<0.001
0006

94 (76 114)
32.9 (27.5 40.1)
128 (90 187)
2.4 (11 5 9)
104 (78 132)

92 (75 112)
31.4 (25 7 38.1)
126 (90 172)
36(1.5 70)
84 (61 112)

0.387
0.002
0.508
<0.001
<0.001

75

72
62
70
67
23
44

0.442
0.58
<0.001
0.358
0085
0.466

64
57

64

19
42

Values expressed in mean :!: SD or median (interquartile range).

Figure 1dKaplan Meier analysis for 3 year major adverse clinical events, stratiﬁed according
to subclinical myocardial necrosis status (rounded to the nearest 0.001 ng/mL).

Baseline characteristics of the study pop
ulation are shown in Table 1 and are strat
iﬁed according to presence or absence of
subclinical myocardial necrosis. Patients
with evidence of subclinical myocardial
necrosis were more likely to be older,
with more cardiovascular risk factors
and history of heart failure, and with
slightly lower renal function at baseline.

Subjects with evidence of subclinical
myocardial necrosis were associated with
an increased 3 year risk of death (HR,
2.39; 95% CI, 1.68 3.40; P , 0.001),
nonfatal MI or stroke (HR, 1.70; 1.09
2.66; P = 0.019), and MACE (HR, 1.98;
1.48 2.65; P , 0.001) (Fig. 1). The risk
prediction appeared to be log linear as de
tectable cTnI levels increased (Fig. 2).

Figure 2dCubic spline curve of HRs for major adverse clinical events at 3 years with cTnI levels.

After adjusting for traditional risk factors,
including Framingham risk factors,
hsCRP, and eCrCl, evidence of subclinical
myocardial necrosis within stable cardiac
diabetic patients remained a signiﬁcant
risk of incident MACE over the ensuing
3 years (HR, 1.48; 1.08 2.01; P = 0.013;
Table 2).
A weak correlation was observed
between the presence of subclinical myo
cardial necrosis and either glycemic con
trol (r = 0.06 and P = 0.044 for HbA1c
versus cTnI) or insulin resistance (r = 0.04
and P = 0.094 for glucose to insulin ratio
versus cTnI). Adjustments with either met
abolic parameters had little impact on the
prognostic value of detectable subclinical
myocardial necrosis within the study co
hort. Figure 3 illustrates similar risk predic
tion for major adverse clinical events at
3 years according to subclinical myocardial
necrosis status stratiﬁed by on treatment
HbA1c using a cut off of 6.5%. The cTnI
levels demonstrated no signiﬁcant interac
tion with statin use or HbA1c levels (P for
interaction $0.20).
CONCLUSIONS The major ﬁnding
of our study is the demonstration that the
presence of subclinical myocardial necro
sis in a respectable proportion of stable
patients with diabetes mellitus has height
ened long term adverse cardiovascular
event risk. We further demonstrated
that such risk may be independent of
underlying glycemic control. These ﬁnd
ings would appear to imply that any
detectable cTnI level should warrant con
sideration for more globally aggressive
risk reduction efforts, including closer
evaluation and long term monitoring,
and such intervention efforts may focus
beyond glycemic control measures.
The concept of diabetes mellitus
being a “coronary artery disease risk
equivalent” has been suggested in several
important studies (6 8) and even for
those subjects with suspected acute coro
nary syndrome but with “normal” cardiac
troponin levels (9). Guideline recommen
dations for routine aspirin prescription and
secondary prevention therefore have been
proposed (10 12). However, recent analy
ses have directly challenged such assertions
(13,14). It is therefore conceivable that dif
ferences in risk proﬁles of patients with
diabetes mellitus may warrant different in
dications of preventive interventions (5).
Using the latest guideline recommenda
tions for the deﬁnition and classiﬁcation
of diabetes mellitus including HbA1c as
sessments (15), the current study provides

The strength of the current study is
the ability to determine the future cardiac
risk in a broad clinical population of
patients with contemporary deﬁnition
and management of diabetes mellitus in
which cardiac troponin measurements
are not routinely performed or clinically
indicated at this time. However, the fact
that all subjects were referred for coronary
angiography, albeit electively, and that
many had relatively preserved renal func
tion, also may represent some degree of
selection bias and may not be fully repre
sentative of the broad population of pa
tients with diabetes mellitus in clinical
practices. Nevertheless, the fact that we
only included those with no revasculari
zation performed within 30 days after
enrollment ensured a population deemed
“medically managed” for their cardiac
conditions. It also should be noted that
our study was limited to a single measure
ment and further work with serial mea
surements is needed to substantiate the
variability of the marker for risk stratiﬁca
tion. Moreover, serial measures will be
useful because it is unclear what impact
various interventions have on cTnI levels
in the subclinical range in these subjects
(24). It also is worth noting that limita
tions of our assays cannot precisely deﬁne
subclinical myocardial necrosis in the
lower range of 0.001 0.008 ng/mL, al
though the diagnostic accuracies of those
with current deﬁnition of subclinical
myocardial necrosis are certain. Most im
portantly, further studies are needed to
determine if the presence of subclinical
myocardial necrosis represents an under
lying process that can be targeted for in
terventions. The presence of detectable
subclinical myocardial necrosis in stable
patients with diabetes mellitus is associ
ated with heightened long term risk for
MACE, independent of traditional risk
factors and glycemic control.
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